Tarsus Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
TARS$73.83+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS
| Pages | |
| Condensed Consolidated Balance Sheets | F-2 |
|---|---|
| Condensed Consolidated Statements of Operations and Comprehensive Loss | F-3 |
| Condensed Consolidated Statements of Stockholders’ Equity | F-4 |
| Condensed Consolidated Statements of Cash Flows | F-5 |
| Notes to the Condensed Consolidated Financial Statements | F-6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.